KEGG   DRUG: Capmatinib hydrochloride
Entry
D10891                      Drug                                   
Name
Capmatinib hydrochloride (USAN);
Capmatinib hydrochloride hydrate (JAN);
Tabrecta (TN)
Product
TABRECTA (Novartis Pharmaceuticals Corporation)
Formula
C23H17FN6O. 2HCl. H2O
Exact mass
502.1087
Mol weight
503.3562
Structure
Simcomp
Class
Antineoplastic
 DG01918  Tyrosine kinase inhibitor
  DG01917  Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
 DG02953  AOX1 substrate
Remark
Therapeutic category: 4291
ATC code: L01EX17
Chemical structure group: DG02081
Product (DG02081): D10891<JP/US>
Efficacy
Antineoplastic, Receptor tyrosine kinase inhibitor
  Disease
Non-small cell lung cancer (MET exon 14 skipping positive) [DS:H00014]
Target
MET* [HSA_VAR:4233v4] [HSA:4233] [KO:K05099]
  Pathway
hsa04014  Ras signaling pathway
hsa04151  PI3K-Akt signaling pathway
hsa05200  Pathways in cancer
hsa05202  Transcriptional misregulation in cancer
hsa05223  Non-small cell lung cancer
  Network
nt06266  Non-small cell lung cancer
Metabolism
Enzyme: CYP3A4 [HSA:1576], AOX1 [HSA:316]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01E PROTEIN KINASE INHIBITORS
    L01EX Other protein kinase inhibitors
     L01EX17 Capmatinib
      D10891  Capmatinib hydrochloride (USAN) <JP/US>
USP drug classification [BR:br08302]
 Antineoplastics
  Molecular Target Inhibitors
   Capmatinib
    D10891  Capmatinib hydrochloride (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  42  Antineoplastics
   429  Miscellaneous
    4291  Other Antitumors
     D10891  Capmatinib hydrochloride (USAN); Capmatinib hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG02081  Capmatinib
     D10891  Capmatinib hydrochloride
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG02081  Capmatinib
     D10891  Capmatinib hydrochloride
  DG02953  AOX1 substrate
   DG02081  Capmatinib
    D10891  Capmatinib hydrochloride
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   MET family
    MET* [HSA_VAR:4233v4]
     D10891  Capmatinib hydrochloride (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D10891
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10891
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10891
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D10891
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D10891
Drug groups [BR:br08330]
 Antineoplastic
  DG01918  Tyrosine kinase inhibitor
   DG01917  Receptor tyrosine kinase inhibitor
    DG02081  Capmatinib
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    DG02081  Capmatinib
  DG02953  AOX1 substrate
   DG02081  Capmatinib
Other DBs
CAS: 1865733-40-9
PubChem: 336445209
LinkDB
KCF data

ATOM        34
            1   C8y C    13.3653  -15.8844
            2   C8y C    13.3653  -17.2839
            3   C8x C    14.6248  -17.9837
            4   C8x C    15.8144  -17.2839
            5   C8y C    15.8144  -15.8844
            6   C8x C    14.6248  -15.1846
            7   C8y C    17.0740  -15.1846
            8   X   F    12.1757  -15.1846
            9   C5a C    12.1757  -17.9837
            10  N1b N    10.9861  -17.2839
            11  O5a O    12.1757  -19.3832
            12  C1a C     9.7965  -17.9837
            13  N5x N    18.2636  -15.8144
            14  N4y N    19.4531  -15.1147
            15  C8y C    19.4531  -13.7152
            16  N5x N    18.2636  -13.0154
            17  C8x C    17.0740  -13.7152
            18  C8y C    20.7827  -15.6045
            19  C8x C    21.6224  -14.4149
            20  N5x N    20.7827  -13.2953
            21  C1b C    21.2025  -16.9340
            22  C8y C    22.6020  -16.9340
            23  C8x C    23.3018  -18.1936
            24  C8y C    24.7013  -18.1936
            25  C8y C    25.4010  -16.9340
            26  C8x C    24.7013  -15.7445
            27  C8x C    23.3018  -15.7445
            28  C8x C    25.4010  -19.3832
            29  C8x C    26.8006  -19.3832
            30  C8x C    27.5003  -18.1936
            31  N5x N    26.8006  -16.9340
            32  X   Cl   17.2200  -19.9500
            33  O0  O    21.9100  -19.9500
            34  X   Cl   17.2200  -19.9500
BOND        35
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     5   7 1
            8     1   8 1
            9     2   9 1
            10    9  10 1
            11    9  11 2
            12   10  12 1
            13    7  13 2
            14   13  14 1
            15   14  15 1
            16   15  16 1
            17   16  17 2
            18    7  17 1
            19   14  18 1
            20   18  19 2
            21   19  20 1
            22   15  20 2
            23   18  21 1
            24   21  22 1
            25   22  23 2
            26   23  24 1
            27   24  25 2
            28   25  26 1
            29   26  27 2
            30   22  27 1
            31   24  28 1
            32   28  29 2
            33   29  30 1
            34   30  31 2
            35   25  31 1
BRACKET     1    15.6100  -20.7900   15.6100  -18.8300
            1    18.4100  -18.8300   18.4100  -20.7900
            1  2
 ORIGINAL  1   32
 REPEAT    1   34

» Japanese version   » Back

DBGET integrated database retrieval system